Stocktoria
Senseonics Holdings, Inc. SENS
Senseonics Holdings, Inc. (SENS) earns a Piotroski F-score of 6/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $35.3M at a -196.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SENS | Senseonics Holdings, Inc. | 6/9 | — | — | +56.9% |
| INIS | RADNOSTIX INC | 3/9 | — | — | -6% |
| ELSE | ELECTRO SENSORS INC | 5/9 | — | 88.3 | — |
| CLIR | ClearSign Technologies Corp | 2/9 | — | — | — |
| FCUV | FOCUS UNIVERSAL INC. | 2/9 | -1.6 | — | — |
| SYPR | SYPRIS SOLUTIONS INC | 2/9 | -2.92 | — | -14.5% |
| HURC | HURCO COMPANIES INC | 4/9 | 9.02 | — | -4.3% |
About Senseonics Holdings, Inc.
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
FAQ
Is SENS financially healthy?
Senseonics Holdings, Inc.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak).
Does SENS pay a dividend?
No, Senseonics Holdings, Inc. does not currently pay a dividend.
How profitable is SENS?
In FY2025, Senseonics Holdings, Inc. had a net margin of -196.0% and a return on equity of -113.2%.
What is the analyst price target for SENS?
The average Wall-Street price target for Senseonics Holdings, Inc. is $13.80, about 74.0% above the recent price, from 5 analysts.
Is SENS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Senseonics Holdings, Inc.: a Piotroski F-score of 6/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.